WO2011093831A3 - Effervescent formulations comprising cefprozil as active agent - Google Patents

Effervescent formulations comprising cefprozil as active agent Download PDF

Info

Publication number
WO2011093831A3
WO2011093831A3 PCT/TR2011/000036 TR2011000036W WO2011093831A3 WO 2011093831 A3 WO2011093831 A3 WO 2011093831A3 TR 2011000036 W TR2011000036 W TR 2011000036W WO 2011093831 A3 WO2011093831 A3 WO 2011093831A3
Authority
WO
WIPO (PCT)
Prior art keywords
cefprozil
active agent
effervescent formulations
effervescent
formulations
Prior art date
Application number
PCT/TR2011/000036
Other languages
French (fr)
Other versions
WO2011093831A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11708946A priority Critical patent/EP2528593A2/en
Publication of WO2011093831A2 publication Critical patent/WO2011093831A2/en
Publication of WO2011093831A3 publication Critical patent/WO2011093831A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Present invention relates to pharmaceutical formulations formulated in effervescent form comprising cefprozil active agent and the process for their preparations.
PCT/TR2011/000036 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent WO2011093831A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11708946A EP2528593A2 (en) 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/00689A TR201000689A1 (en) 2010-01-29 2010-01-29 Solid dosage forms containing cefprozil.
TR2010/00689 2010-01-29

Publications (2)

Publication Number Publication Date
WO2011093831A2 WO2011093831A2 (en) 2011-08-04
WO2011093831A3 true WO2011093831A3 (en) 2012-02-23

Family

ID=44065360

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000032 WO2011093828A2 (en) 2010-01-29 2011-01-28 Solid dosage forms comprising cefprozil
PCT/TR2011/000036 WO2011093831A2 (en) 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000032 WO2011093828A2 (en) 2010-01-29 2011-01-28 Solid dosage forms comprising cefprozil

Country Status (3)

Country Link
EP (1) EP2528593A2 (en)
TR (1) TR201000689A1 (en)
WO (2) WO2011093828A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357086A (en) * 2011-11-01 2012-02-22 上海理工大学 Cefprozil orally disintegrating tablets
WO2013109201A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising cefprozil and clavulanic acid
CN111658616B (en) * 2020-05-22 2022-03-15 广州白云山医药集团股份有限公司白云山制药总厂 Cefprozil dry suspension and preparation method thereof
CN114886859A (en) * 2022-06-09 2022-08-12 哈尔滨凯程制药有限公司 Cefprozil granules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1145711A1 (en) * 2000-04-12 2001-10-17 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
CN100417383C (en) * 2006-03-07 2008-09-10 中国药科大学 Effervescent tablet containing cefixime and its preparing method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520022A (en) 1983-01-28 1985-05-28 Bristol-Myers Company Substituted vinyl cephalosporins
CN101032489B (en) * 2006-03-08 2011-06-15 上海秀新臣邦医药科技有限公司 Cefprozil dispersible table and the preparing method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1145711A1 (en) * 2000-04-12 2001-10-17 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
CN100417383C (en) * 2006-03-07 2008-09-10 中国药科大学 Effervescent tablet containing cefixime and its preparing method

Also Published As

Publication number Publication date
TR201000689A1 (en) 2011-08-22
WO2011093828A3 (en) 2012-02-23
WO2011093831A2 (en) 2011-08-04
EP2528593A2 (en) 2012-12-05
WO2011093828A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2011093832A3 (en) Stable efervescent formulations comprising cefaclor
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2012021715A3 (en) Stable formulations of linaclotide
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2011130615A3 (en) Preparation of lacosamide
IL220679A (en) Production method of solid preparations containing alkaline active pharmaceutical ingredients and the solid preparations produced by the method
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2010021607A3 (en) Pharmaceutical formulation
WO2012040804A3 (en) Synergistic combinations of triazoles, strobilurins and benzimidazoles, uses, formulations, production processes and applications using the same
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
EP2404591A4 (en) Cosmetic preparation, method for producing same, composition for cosmetic preparations, cosmetic preparation containing the composition for cosmetic preparations and method for producing same, and cleanser for industrial use
WO2012130820A3 (en) Isopentyl esters for the use in cosmetic, dermatological, or pharmaceutical compositions
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
IL227024A (en) Amino-substituted 3-heteroaroylamino-propionic acid derivatives, process for the preparation of such compounds, uses thereof in the preparation of pharmaceuticals and pharmaceutical compositions comprising the same
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
HK1188983A1 (en) Novel dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
MX2014014579A (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
EP2799082A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
WO2012093973A3 (en) Compositions in the form of tablets comprising acarbose
WO2012036414A3 (en) Cosmetic composition comprising a fermented soybean extract fraction as an active ingredient
WO2012007758A3 (en) Pharmaceutical formulations
WO2013074048A3 (en) Tablet forms comprising quetiapine fumarate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11708946

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011708946

Country of ref document: EP